Author

Hasan Issa

Goethe University FrankfurtORCID 0000-0002-9760-9618Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Jan‐Henning KlusmanniD· 4 shared K. SchuscheliD· 4 shared Dirk HeckliD· 3 shared José Gonçalves-DiasiD· 3 shared Lonneke VerbooniD· 2 shared Raj BhayadiaiD· 2 shared Ágnes OszláncziiD· 1 shared Aimy SebastianiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Jan‐Henning KlusmannORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Integrative enhancer discovery identifies functional enhancer dependencies in pediatric acute myeloid leukemia

Leah Schüler, Robert E. Winkler, José Gonçalves-Dias, K Schuschel, Hasan Issa, Lonneke Verboon, Xiaoyan Wei, Ronay Çetin, Yves Matthess, Manuel Kaulich, Stefan Hüttelmaier, Raj Bhayadia, Dirk Heckl, Jan‐Henning Klusmann

This study identifies functional enhancer dependencies in pediatric AML using an integrative approach, revealing H-ME as an RNA-independent regulator of MYB.

bioRxiv · Aug 21, 2026 · PreprintCancer Biology

DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia

Lonneke Verboon, Sonali P. Barwe, Meredith Tavenner, Joshua R. Faust, Hasan Issa, José Gonçalves-Dias, K. Schuschel, Raj Bhayadia, Patrick H. van Berkel, Aimy Sebastian, Rhonda E. Ries, Sophie Paczesny, Soheil Meshinchi, Johann K. Hitzler, Yana Pikman, , Anilkumar Gopalakrishnapillai

This study identifies DLK1 as a GATA1s-driven dependency in Down syndrome-associated myeloid leukemia, showing it as a therapeutic target with preclinical efficacy in PDX models.

Blood Advances · Apr 7, 2026Peer-reviewedCancer Biology

Activation of the TP53 pathway is a therapeutic vulnerability in NUP98::KDM5A+ pediatric AML

L. Cifarelli, Hasan Issa, Ludovica Proietti, K Schuschel, Lucie Gack, Katja Menge, Christian H. Ihling, Meike Vogler, Andrea Sinz, Jan‐Henning Klusmann, Dirk Heckl

This study identifies TRIP13 as a developmentally restricted dependency in NUP98::KDM5A+ pediatric AML, showing that its inhibition reactivates TP53 and kills leukemic cells.

bioRxiv · Sep 11, 2025 · PreprintCancer Biology

Single cell transcriptional evolution of myeloid leukaemia of Down syndrome

Mi K. Trinh, K Schuschel, Hasan Issa, Rebecca Thomas, Conor Parks, Ágnes Oszlánczi, Toochi Ogbonnah, Di Zhou, Lira Mamanova, Elena Prigmore, Emilia Robertson, Angus Hodder, Anna Wenger, Nathaniel D. Anderson, Holly J. Whitfield, , Sam Behjati

The paper examines the transcriptional evolution of myeloid leukaemia in Down syndrome by analyzing single-cell RNA sequencing data from patient samples and fetal tissues.

bioRxiv · Apr 1, 2025 · PreprintCancer Biology